Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis ; volume:55 ; number:11 ; day:1 ; month:11 ; year:2023 ; pages:2346-2356 ; date:11.2023
Experimental & molecular medicine ; 55, Heft 11 (1.11.2023), 2346-2356, 11.2023
- Creator
-
Choi, Jin Sun
Kim, Ji-Young
Ahn, Min-Joo
Jang, Hanbit
Song, Seungtaek
Choi, Sung Hoon
Park, Ye-Soo
Jo, Sungsin
Kim, Tae-Hwan
Shim, Seung Cheol
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s12276-023-01103-z
- URN
-
urn:nbn:de:101:1-2024022109582555077067
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-14T10:52:24+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Choi, Jin Sun
- Kim, Ji-Young
- Ahn, Min-Joo
- Jang, Hanbit
- Song, Seungtaek
- Choi, Sung Hoon
- Park, Ye-Soo
- Jo, Sungsin
- Kim, Tae-Hwan
- Shim, Seung Cheol
- SpringerLink (Online service)
Other Objects (12)
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
![Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy